Patents by Inventor Kyle Lorentsen

Kyle Lorentsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPIES COMPRISING T-CELL REDIRECTING THERAPIES AND AGONISTIC ANTI-IL-2R ANTIBODIES OR FRAGMENTS THEREOF
    Publication number: 20260102487
    Abstract: Methods of treating cancer or enhancing an anti-cancer effect associated with administration of a T-cell redirecting therapy in a subject in need thereof, comprising administering to the subject an anti-IL-2R?? heavy chain-only antibody or antigen binding fragment thereof in combination with a T-cell redirecting therapy are disclosed, along with uses of anti-IL-2R?? heavy chain-only antibodies and antigen binding fragments thereof and/or T-cell redirecting therapies in the manufacture of a medicament adapted for use in a method described herein; pharmaceutical compositions comprising anti-IL-2R?? heavy chain-only antibodies and antigen binding fragments thereof and/or T-cell redirecting therapies for use in a method described herein; and combination products.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 16, 2026
    Applicant: AMGEN INC.
    Inventors: Katherine HARRIS, Kyle LORENTSEN, Harbani Kaur MALIK CHAUDHRY, Kaitlyn LOUGHLIN, Deepali V. SAWANT, Hayley MA, Volha PRYSHCHEP, Raul Gabriel LAZARO
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 12590163
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: August 29, 2023
    Date of Patent: March 31, 2026
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 11884735
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20240018250
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: August 29, 2023
    Publication date: January 18, 2024
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE
    Publication number: 20230242653
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Application
    Filed: February 3, 2023
    Publication date: August 3, 2023
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin